GlassScriptPhysician profile
Thomas M Montagne
NPI 1326019316
$4,335.07
in general payments reported to CMS, 2019-2025
34 companies · $627 in 2025
The $627 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $210 · 2021: $12.14 · 2022: $756 · 2023: $1,033 · 2024: $772 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395 · Education: $37.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.86 |
| Education | $37.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,573.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.15 | 2019-2023 | Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $335.80 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $288.86 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $186.08 | 2020-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $179.53 | 2019-2025 | Ocaliva |
| Pfizer INC. | $177.04 | 2019-2025 | |
| Boston Scientific Corporation | $131.00 | 2023-2024 | Apollo Esg System, Exalt Model D |
| Phathom Pharmaceuticals, INC. | $95.30 | 2024-2025 | Voquezna |
| Ucb, INC. | $92.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.96 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $74.21 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Genzyme Corporation | $72.00 | 2024-2025 | |
| Braintree Laboratories, INC. | $65.63 | 2020-2023 | Sutab |
| Daiichi Sankyo INC. | $62.64 | 2022-2024 | Injectafer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $43.02 | 2019 | |
| Organon LLC | $39.17 | 2023 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $39.11 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $38.91 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $37.79 | 2020-2022 | |
| Celltrion USA INC. | $37.10 | 2024 | Zymfentra |
| Ardelyx, INC. | $33.26 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $33.26 | 2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $33.18 | 2022 | |
| Madrigal Pharmaceuticals | $32.04 | 2025 | Rezdiffra |
| Lilly USA, LLC | $27.66 | 2025 | Omvoh |
| Sandoz INC. | $19.76 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.88 | 2025 | Dupixent |
| Medtronic, INC. | $15.69 | 2023 | Gi Genius |
| Endo Pharmaceuticals INC. | $13.18 | 2019 | |
| Pharmacosmos Therapeutics INC. | $13.11 | 2023 | Monoferric |
| Shionogi INC | $13.07 | 2019 | |
| Shire North American Group INC | $13.02 | 2019 | |
| Allergan, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Montagne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.